Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

ARNA 4.51 +0.07 (1.58%)
price chart
Company Shares of Arena Pharmaceuticals, Inc. Rally 1.14%
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose by 1.14% in the past week and 1.83% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 2.34% and the outperformance increases to 2.62% for the last 4 weeks.
Stock Insights on Arena Pharmaceuticals Inc (NASDAQ:ARNA)
[PRNewswire] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) announced that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue ...
3 Biotech Stocks Are Getting Crushed – Arena Pharmaceuticals, Inc. (NASDAQ ...  Wall Street Observer
Stocks Plunging - Arena Pharmaceuticals (ARNA), Paragon Offshore (PGN ...  Investor Wired
Analyst Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The mean estimate for the short term price target for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stands at $5.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $8 ...
Can Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise Analysts this Quarter?
In the most recent quarter, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported an earnings surprise of 28.57% when the firm last announced their results for the period ending on 2015-03-31.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Price Target Update  OTC Outlook
Morning Alert: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Gilead Sciences ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) belongs to Healthcare sector. Its weekly performance is 2.54%. On last trading day company shares ended up $4.44.
Early Day Buzz: Centene Corp. (NYSE:CNC), Nokia Corporation (ADR) (NYSE ...  Property Mentor
Biotech Stocks getting no love - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Mr. Hoffman is expected to remain in his current role at Arena until July 10, 2015. “Robert has been a valuable member of our management team and, on behalf of myself and the company, I thank him for his years of leadership and service to Arena,” said ...
Arena Pharmaceuticals, Inc. Short Interest Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has seen a shortfall of 260,771 shares or 0.8% in the short interest. The remaining shorts are 12.8% of the total floated shares.
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Large Outflow of ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) managed to eke out gains of 1.65% in intraday trade. The share price increased by 0.07 points to $4.3.
Arena Pharmaceuticals Announces the Departure of Chief Financial Officer  MarketWatch
Zacks Short Term Rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a hold, according to the latest average broker rating of 2.5. The number of analysts in this rating is 6. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation ...
Arena Pharmaceuticals, Inc. Price Target Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The mean estimate for the short term price target for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stands at $5.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $8 ...